Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "ArtifactAssessment",
"id" : "179693",
"meta" : {
"versionId" : "6",
"lastUpdated" : "2023-12-04T21:34:42.955Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/certainty-of-evidence"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ArtifactAssessment 179693</b></p><a name=\"179693\"> </a><a name=\"hc179693\"> </a><a name=\"179693-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 6; Last updated: 2023-12-04 21:34:42+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-certainty-of-evidence.html\">CertaintyOfEvidence</a></p></div><p><b>Artifact URL</b>: <a href=\"https://fevir.net/resources/ArtifactAssessment/179693\">https://fevir.net/resources/ArtifactAssessment/179693</a></p><p><b>Artifact Description</b>: </p><div><p>This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.</p>\n</div><p><b>identifier</b>: FEvIR Object Identifier/179693</p><p><b>title</b>: Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)</p><p><b>artifact</b>: <a href=\"Evidence-55.html\">14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: Rating</p><p><b>summary</b>: </p><div><p>Low certainty due to inconsistency and risk of bias</p>\n</div><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Overall}\">Overall certainty</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating low}\">Low quality</span></p><blockquote><p><b>component</b></p><p><b>informationType</b>: Rating</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type PublicationBias}\">Publication bias</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating no-concern}\">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>informationType</b>: Rating</p><p><b>summary</b>: </p><div><p>There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.</p>\n</div><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Inconsistency}\">Inconsistency</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating serious-concern}\">serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>informationType</b>: Rating</p><p><b>summary</b>: </p><div><p>Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.</p>\n</div><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Imprecision}\">Imprecision</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating no-concern}\">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>informationType</b>: Rating</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type Indirectness}\">Indirectness</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating no-concern}\">no serious concern</span></p></blockquote><blockquote><p><b>component</b></p><p><b>informationType</b>: Rating</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-type RiskOfBias}\">Risk of bias</span></p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/certainty-rating serious-concern}\">serious concern</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>InformationType</b></td><td><b>Summary</b></td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td>Rating</td><td><div><p>No blinding (no placebo control) in the largest trial</p>\n</div></td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/181513 SEVCO:00035}\">Lack of blinding</span></td><td><span title=\"Codes:{http://hl7.org/fhir/certainty-rating present}\">present</span></td></tr></table></blockquote></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-url",
"valueUri" : "https://fevir.net/resources/ArtifactAssessment/179693"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-description",
"valueMarkdown" : "This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence."
}
],
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net",
"value" : "179693",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"title" : "Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"artifactReference" : {
🔗 "reference" : "Evidence/55",
"type" : "Evidence",
"display" : "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"
},
"content" : [
{
"informationType" : "rating",
"summary" : "Low certainty due to inconsistency and risk of bias",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Overall",
"display" : "Overall certainty"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "low",
"display" : "Low quality"
}
]
}
],
"component" : [
{
"informationType" : "rating",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "PublicationBias",
"display" : "Publication bias"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "no-concern",
"display" : "no serious concern"
}
]
}
]
},
{
"informationType" : "rating",
"summary" : "There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Inconsistency",
"display" : "Inconsistency"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "serious-concern",
"display" : "serious concern"
}
]
}
]
},
{
"informationType" : "rating",
"summary" : "Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Imprecision",
"display" : "Imprecision"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "no-concern",
"display" : "no serious concern"
}
]
}
]
},
{
"informationType" : "rating",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "Indirectness",
"display" : "Indirectness"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "no-concern",
"display" : "no serious concern"
}
]
}
]
},
{
"informationType" : "rating",
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-type",
"code" : "RiskOfBias",
"display" : "Risk of bias"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "serious-concern",
"display" : "serious concern"
}
]
}
],
"component" : [
{
"informationType" : "rating",
"summary" : "No blinding (no placebo control) in the largest trial",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/181513",
"code" : "SEVCO:00035",
"display" : "Inadequate blinding of participants"
}
],
"text" : "Lack of blinding"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/certainty-rating",
"code" : "present",
"display" : "present"
}
]
}
]
}
]
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change